Trial Profile
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Mar 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Sunitinib
- Indications Clear cell sarcoma; Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 214
- Sponsors Bristol-Myers Squibb
- 27 Jan 2024 Longer follow-up data (minimum, 7.5 years) presented at the 2024 Genitourinary Cancers Symposium.
- 22 Jan 2024 Results published in the Bristol-Myers Squibb Media Release
- 17 Jan 2024 According to a Bristol-Myers Squibb media release, unprecedented eight-year results data from this study will be at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU) to be held from January 25-27 in San Francisco, California.